Elios Therapeutics presents new Phase IIb data for personalized cancer vaccine in high-risk melanoma patients

Elios Therapeutics presents new Phase IIb data for personalized cancer vaccine in high-risk melanoma patients. (Credit: Willfried Wende from Pixabay)